Zynex announces workforce reduction and provides update on Tricare payment suspension

Zynex (ZYXI) has reduced its corporate workforce by 86 roles, or 14% of total employees, effective June 18, anticipating $5 million in annualized cost savings as part of a strategic adjustment to its billing and order processing. This restructuring follows a significant stock decline of over 70% in the past six months and a disappointing Q1 2025, where the company reported a $10.4 million net loss and substantially missed revenue and EPS forecasts. While Zynex maintains a strong liquidity position with a 3.46 current ratio, it continues to grapple with unresolved TRICARE reimbursement issues, with future revenue growth largely dependent on the 2026 launch of its NICO Pulse Oximeter.

Analysis

Zynex, Inc. (ZYXI) is undertaking a significant corporate restructuring, eliminating 14% of its workforce to generate approximately $5 million in annualized cost savings. This move follows an exceptionally weak first quarter of 2025, in which the company's revenue of $26.58 million fell nearly 50% short of the $53.47 million forecast and declined sharply from $46.5 million in the prior-year period. The revenue collapse resulted in a net loss of $10.4 million and an EPS of -$0.33, a stark contrast to the projected profit. This underperformance has been reflected in its stock price, which has plummeted over 70% in the past six months. While the company attributes the layoffs to a strategic adjustment in its billing and order processing, it is simultaneously navigating an unresolved temporary payment suspension from TRICARE, which poses a material risk to future revenue. Despite these severe operational and financial challenges, Zynex maintains a strong liquidity position with a current ratio of 3.46 and $24 million in cash. However, a return to growth appears distant, with the company's outlook heavily reliant on the launch of its NICO Pulse Oximeter, from which it does not expect to generate revenue until 2026.

Key Decisions for Investors

• Investors should view the recent workforce reduction as a defensive reaction to severe top-line deterioration, recognizing that the projected $5 million in savings does not address the core issues of collapsing revenue and the unresolved TRICARE payment suspension.
• Given the significant Q1 earnings miss and the over 70% stock decline, any potential investment thesis is now a high-risk turnaround story contingent on distant catalysts, primarily the successful commercial launch of the NICO Pulse Oximeter in 2026.
• While the company's current ratio of 3.46 provides a near-term liquidity cushion, the $10.4 million quarterly net loss against a $24 million cash balance indicates a significant cash burn rate that must be monitored closely.